Cartesian Therapeutics Engages Investors in Key Conferences
Frederick, Maryland - Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is excited to announce its participation in several prominent investor conferences in the upcoming weeks. As a leader in mRNA cell therapies focused on autoimmune diseases, the Company's management team is eager to connect with investors and share insights into their innovative advancements.
Fireside Chats and Presentations
This vibrant schedule kicks off with a fireside chat at the H.C. Wainright & Co. 3rd Annual Cell Therapy Virtual Conference, set for 1:00 p.m. ET on an upcoming Tuesday. This event serves as an excellent platform for the Company to discuss its mission of developing groundbreaking therapies.
Following this, Cartesian Therapeutics will deliver a presentation at the TD Cowen 45th Annual Health Care Conference on a Monday afternoon. This presentation is particularly significant as it aligns with the Company's strategic vision for growth and outreach in the healthcare sector.
Furthermore, on another Monday in March, Cartesian will participate in a fireside chat at the Leerink Global Healthcare Conference. This event is anticipated to draw significant attention from various stakeholders looking to understand the future trajectory of mRNA therapies.
Webcast Accessibility and Replay
For those unable to attend the live events, Cartesian Therapeutics plans to provide a live webcast. This will be accessible through the Events section of the Company's website, and an archived replay will be available for a limited time after the events. This approach ensures that every interested party gets a chance to hear about the Company’s innovative strategies and therapeutic advancements.
Innovation in mRNA Therapies
At the core of Cartesian Therapeutics is their pioneering work in mRNA cell therapies. The lead asset, Descartes-08, is currently undergoing Phase 2b trials for treating patients with generalized myasthenia gravis, alongside its Phase 2 development for systemic lupus erythematosus. Notably, there are plans for a Phase 2 basket trial in additional autoimmune conditions, showcasing the Company’s commitment to comprehensive therapeutic solutions.
The Future of Cartesian Therapeutics
Alongside Descartes-08, the Company is advancing other clinical-stage assets like Descartes-15, which is a next-generation, autologous anti-BCMA mRNA CAR-T. These developments position Cartesian Therapeutics as a key player in the biotechnology sector, fostering hope and treatment options for patients suffering from autoimmune diseases.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc. is dedicated to transforming the treatment landscape for autoimmune diseases through mRNA technology. The Company is committed to addressing unmet medical needs, ensuring that its innovations translate into real-world benefits for patients. Cartesian’s tireless efforts are reflected in its expanding pipeline, which is designed to bring forward therapeutic solutions that truly make a difference.
Contact Information
Investor Contact
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
Frequently Asked Questions
What is the purpose of the investor conferences?
The investor conferences aim to showcase Cartesian Therapeutics' advancements in mRNA therapies and foster connections with stakeholders.
What is Descartes-08?
Descartes-08 is an mRNA CAR-T therapy currently in clinical trials for autoimmune diseases such as generalized myasthenia gravis.
Will the presentations be accessible to the public?
Yes, a live webcast will be available, along with an archived replay on the Company's website.
How is Cartesian Therapeutics innovating in healthcare?
By developing novel mRNA therapies, Cartesian aims to address significant gaps in treatment options for autoimmune diseases.
Who can I contact for investor inquiries?
Megan LeDuc is the Associate Director of Investor Relations and can be contacted via the provided email.
